Spruce Biosciences (SPRB)

Develops tralesinidase alfa enzyme replacement therapy (TA-ERT) for mucopolysaccharidosis type IIIB, also called Sanfilippo syndrome type B, a neurodegenerative disease. Delivered by intracerebroventricular infusion, TA-ERT replaces deficient NAGLU enzyme activity in the central nervous system and reduces heparan-sulfate accumulation.

Focuses its regulatory and commercial plan on a U.S. filing and possible launch for TA-ERT, while holding worldwide rights to the enzyme-replacement portfolio. SPR202, a preclinical anti-corticotropin-releasing-hormone monoclonal antibody for congenital adrenal hyperplasia, is the only active pipeline asset.

Uses licensed assets, external partners and contractors while building selected regulatory, medical and commercial capabilities. The accelerated-approval approach combines interventional and natural-history data around cerebrospinal-fluid heparan-sulfate non-reducing ends as a potential surrogate endpoint; it remains subject to FDA acceptance, manufacturing readiness and a confirmatory study. No product is approved, and current commercialization depends on contractual rights, third-party execution and regulatory clearance.